Godlike Productions - Discussion Forum
Users Online Now: 1,397 (Who's On?)Visitors Today: 356,252
Pageviews Today: 559,418Threads Today: 211Posts Today: 3,407
06:14 AM


Back to Forum
Back to Forum
Back to Thread
Back to Thread
REPORT ABUSIVE MESSAGE
Subject Parkinson´s drug prompts brain cell growth
Poster Handle Homie the Shadow
Post Content
[link to www.newscientist.com]

16:55 01 July 2005
NewScientist.com news service
Rowan Hooper

A drug that relieves the symptoms of Parkinson’s disease – but was controversially withdrawn over toxicity fears – has now been shown to stimulate growth of the nerve fibres damaged by the disease.

When delivered directly to the brain, glial cell-line derived neurotrophic factor (GDNF) had been shown to stimulate regrowth of cells in animal models of Parkinson’s. But this is the first time regrowth has been seen in the human brain, says Steven Gill, a neurosurgeon at Frenchay Hospital, Bristol, UK.

Gill was running a trial study where five patients with advanced Parkinson’s disease were fitted with a tiny catheter that delivered GDNF direct to the putamen, part of the basal ganglia in the centre of the brain. In the putamen of Parkinson’s patients the chemical messenger dopamine is lost.

The symptoms of Parkinson’s - which include uncontrollable shaking and trembling - were reduced in all five patients. They showed dramatic improvements with respect to their motor skills, verbal memory, facial expressions and motivation.
Frustrating situation

However, Amgen, the company that makes GDNF, withdrew the drug after fears over its toxicity and a second trial of 34 patients was halted. That was despite the fact that the toxicity trials involved testing far higher doses of GDNF on animal models, and that none of the human subjects had showed any ill-effects.

“For people with Parkinson’s disease the situation is frustrating when we’ve seen significant benefits of GDNF,” says Gill. In the US, some patients involved in halted clinical trials are taking legal action to try to force Amgen to supply them with the drug.

Gill, Seth Love, and colleagues were able to demonstrate the regrowth of cells in the human brain after a patient in the original GDNF trial later died of a heart attack. Examination of his brain showed that nerve fibres in the putamen had “sprouted” – specifically in the substantia nigra region where the cells that produce dopamine are sited.
 
Please verify you're human:




Reason for reporting:







GLP